Background Three transmucosal fentanyl products have recently been licensed for cancer-
related breakthrough pain: a sublingual tablet, a buccal/sublingual tablet and a nasal spray …

Oral normal-release morphine has long been considered the gold-standard treatment for
cancer breakthrough pain. However, its relatively long time to analgesic onset, delay in …

Objective To compare the efficacy of fentanyl effervescent buccal tablet (FBT), sublingual
oral transmucosal fentanyl citrate (ODT) and compressed lozenge oral transmucosal …

Overview Cancer pain presents a significant clinical challenge. Even when background pain
is effectively controlled, patients often experience episodes of breakthrough cancer pain …

Background and objectives: A number of transmucosal fentanyl formulations have been
developed for the management of breakthrough cancer pain (BTCP). Sublingual delivery of …

Formulations of fentanyl that use buccal, sublingual, or nasal transmucosal routes of
administration have been developed for the treatment of BTP in opioid-tolerant patients with …

Objective: The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral
transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) …

Breakthrough cancer pain (BTcP) is an episode of severe pain that “breaks through” a
period of persistent pain at least partly controlled by a stable opioid regimen. Although …

Breakthrough pain (BTP) is highly prevalent (59.2%) in chronic cancer patients and normally
needs rescue treatments' with opioids when pain flares up. Transmucosal oral/nasal fentanyl …

Background: Head and neck (H&N) cancers account for about 5% of all malignant tumours.
Pain is one of the most feared consequences of H&N neoplasms and is experienced by up …